Allison Betof Warner, MD, PhD, Stanford Medicine, discusses the FDA approval of tumor-infiltrating lymphocytes (TIL) therapy in February 2024 for treating checkpoint-refractory metastatic melanoma. Despite a 31% response rate, many patients may require further treatment post-TIL due to T-cell exhaustion. This highlights the potential to rescue exhausted TILs with checkpoint blockade but raises concerns about the safety of immunotherapy rechallenge, especially regarding the risk of increased toxicity after administering a large load of tumor-specific T-cells. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Негізгі бет Exploring TIL therapy & IO rechallenge in checkpoint refractory melanoma
Пікірлер